PTGS1 and coronary artery disorder: Aspirin, for example, is a well-established antiplatelet drug in the secondary prevention of CAD patients, which irreversibly inhibits cyclooxygenase-1 (COX1), also named as prostaglandin-endoperoxide synthase 1 (PTGS1), and suppresses the biosynthesis thromboxane A2 (TxA2) (Depta and Bhatt, 2015).